Summary
PBE Chart
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Making its debut on 06/23/2005, smart beta exchange traded fund Invesco Biotechnology & Genome ETF (PBE) provides investors broad exposure to the Health Care ETFs category of the market.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on June 23, 2005.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005.
Invesco Biotechnology & Genome ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 441 | $28,559.44 | $39,480.52 | $10,921.08 | 38.24% |
 Kyle P. Smith NewEdge Wealth LLC | 15,701 | $1.03M | $1.4M | $370,157.97 | 35.83% |
 Michael Byun SageView Advisory Group LLC | 1,659 | $136,287 | $150,421.53 | $14,134.53 | 10.37% |
| SM Sarah Moore BOS Asset Management LLC | 2,562 | $210,103.13 | $233,282.91 | $23,179.78 | 11.03% |
| SJC Samuel J. Conte II Massachusetts Wealth Management | 17,814 | $1.15M | $1.62M | $469,066.24 | 40.72% |
Invesco Biotechnology & Genome ETF (PBE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Invesco Biotechnology & Genome ETF ever had a stock split?
Invesco Biotechnology & Genome ETF Profile
| ARCA Exchange | US Country |
Overview
The fund investigated herein primarily commits itself to investing in a portfolio that closely mirrors the performance of the underlying index. This index predominantly consists of common stock from U.S. companies operating within the biotechnology and genome sectors. By directing at least 90% of its total assets towards securities that form the underlying index, the fund aims to partake directly in the growth and development of these cutting-edge industries. The selection criteria for these investments are rigorously defined, focusing on companies heavily involved in the research, development, manufacture, marketing, and distribution of biotechnological products, services, and processes. This focused investment approach categorizes the fund as non-diversified, signifying a strategic concentration in its chosen domain rather than spreading its investments across a wide array of sectors.
Products and Services
- Biotechnological Products
Investments pertaining to this category focus on firms that are in the business of researching, developing, and bringing to market innovative biotechnological products. These could range from novel pharmaceuticals to groundbreaking agricultural biotech solutions, embodying the cutting edge of genetic and molecular science.
- Genomic Services
The fund allocates resources towards companies specializing in genomic services. This includes businesses dedicated to gene sequencing, analysis, and editing. These genomic services represent the forefront of personalized medicine and advanced diagnostics, offering potential leaps in treating and understanding genetic disorders.
- Research and Development (R&D)
Part of the fund's investments supports the fundamental R&D efforts of biotechnology firms. These companies are engaged in the basic science and applied research necessary to develop the next generation of biotechnological applications and therapeutic interventions, underscoring the importance of continual innovation in this field.
- Manufacture and Marketing
This category focuses on investing in companies that not only develop biotech products but also possess the capacity to manufacture and market them. It encompasses businesses that have completed the full cycle of bringing a biotechnological innovation from the laboratory to the market, emphasizing the fund's interest in companies that can realize their scientific advancements commercially.
